Key Takeaways
• Prime assembly can insert DNA segments more than 13 times larger than earlier methods
• The technique enables replacement of entire faulty genes in a single step
• It avoids double strand DNA breaks, making it safer for cells
• Works in non dividing cells like neurons and heart cells
• Demonstrated successful insertion of large genes including one linked to Duchenne muscular dystrophy
A major advance in genetic engineering is bringing scientists closer to the long standing goal of replacing entire defective genes in a single step. Researchers have introduced a new method called prime assembly, a technique that dramatically expands the capabilities of modern gene editing.
The study, published in Nature on April 29, 2026, was led by Bin Liu at The Ohio State University College of Medicine, alongside collaborators Erik Sontheimer and Wen Xue from UMass Chan Medical School.
Prime assembly builds on earlier advances in CRISPR gene editing, specifically a method known as twin prime editing. Instead of cutting both strands of DNA, the system creates precise single stranded extensions called flaps at a targeted location in the genome. A matching DNA template is then seamlessly integrated into the genome through a process similar to molecular assembly inside living cells.
What sets this method apart is its scale. Researchers achieved insertion of DNA fragments up to 11.3 kilobase pairs, including a full length gene associated with Duchenne muscular dystrophy. Earlier techniques struggled to insert sequences larger than a few hundred base pairs. The new approach also reached insertion efficiencies of up to 50 percent for smaller segments, a significant improvement over previous tools.
One of the most important advantages of prime assembly is its safety profile. Traditional gene editing often relies on creating double strand DNA breaks, which can damage cells and activate stress responses such as tumor suppression pathways. Prime assembly avoids this by using only single strand nicks, making the process far less toxic.
This also allows the method to function in non dividing cells, a critical limitation of older techniques. Cells like neurons and cardiomyocytes do not actively divide, which has historically made them difficult targets for gene therapy. By bypassing the need for repair pathways that are only active during cell division, prime assembly could open the door to treating conditions that affect the brain and heart.
The researchers further improved the system by using AZD-7648, a molecule that enhances both the precision and efficiency of DNA insertion. With this addition, unintended edits were reduced to near background levels, increasing confidence in the method’s reliability.
Rather than fixing mutations one by one, prime assembly introduces the possibility of swapping out entire faulty genes with healthy versions. This could simplify treatment for diseases caused by many different mutations within the same gene. As a proof of concept, the team successfully inserted a CAR gene into immune cells, a step relevant to next generation cancer therapies.
Looking ahead, the researchers plan to test the technology in animal models to evaluate safety and effectiveness in living organisms. Delivery remains a key challenge, with approaches such as lipid nanoparticles and viral vectors being explored to transport the editing machinery into the body.
If successful, prime assembly could represent a major leap forward in gene therapy, shifting the field from precise edits toward full genetic replacement and offering new hope for treating complex inherited diseases.